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ABSTRACT
Objective To investigate whether placebo effects can
experimentally be separated into the response to three
components—assessment and observation, a
therapeutic ritual (placebo treatment), and a supportive
patient-practitioner relationship—and then progressively
combined to produce incremental clinical improvement in
patients with irritable bowel syndrome. To assess the
relative magnitude of these components.
Design A six week single blind three arm randomised
controlled trial.
Setting Academic medical centre.
Participants 262 adults (76% women), mean (SD) age 39
(14), diagnosed by Rome II criteria for and with a score of
≥150 on the symptom severity scale.
Interventions For three weeks either waiting list
(observation), placebo acupuncture alone (“limited”), or
placebo acupuncture with a patient-practitioner
relationship augmented by warmth, attention, and
confidence (“augmented”). At three weeks, half of the
patients were randomly assigned to continue in their
originally assigned group for an additional three weeks.
Main outcome measures Global improvement scale
(range 1-7), adequate relief of symptoms, symptom
severity score, and quality of life.
ResultsAt threeweeks, scores on the global improvement
scale were 3.8 (SD 1.0) v 4.3 (SD 1.4) v 5.0 (SD 1.3) for
waiting list versus “limited” versus “augmented,”
respectively (P<0.001 for trend). Theproportionofpatients
reporting adequate relief showed a similar pattern: 28%
on waiting list, 44% in limited group, and 62% in
augmented group (P<0.001 for trend). The same trend in
response existed in symptom severity score (30 (63) v 42
(67) v 82 (89), P<0.001) and quality of life (3.6 (8.1) v 4.1
(9.4) v 9.3 (14.0), P<0.001). All pairwise comparisons
between augmented and limited patient-practitioner
relationship were significant: global improvement scale
(P<0.001), adequate relief of symptoms (P<0.001),
symptomseverity score (P=0.007), quality of life (P=0.01).
Results were similar at six week follow-up.
Conclusion Factors contributing to the placebo effect can
be progressively combined in a manner resembling a
graded dose escalation of component parts. Non-specific
effects can produce statistically and clinically significant
outcomes and the patient-practitioner relationship is the
most robust component.
Trial registration Clinical Trials NCT00065403.
INTRODUCTION
Aside from the provision of a specific therapeutic
regimen, a medical encounter might elicit non-specific
or contextual benefits or what are most often called
placebo effects. Experimental settings seek to contain
these “nuisance” effects with placebo controls. Such
non-specific effects in a clinical setting can theoretically
be separated into three components: a patient’s
response to observation and assessment (Hawthorne
effects), thepatient’s response to the administrationof a
therapeutic ritual (placebo treatment), and thepatient’s
response to the patient-practitioner interaction.1-3 We
tested this by determining whether these distinct
potential contributions to clinical care canbe separated
and then combined incrementally under controlled
conditions to produce progressive improvement in
clinical outcomes in a manner resembling a graded
dose escalationof component parts.Wealso quantified
theextent towhich thepatient-practitioner relationship
enhances the effects of a placebo treatment alone and
whether a placebo intervention is more effective than
no treatment/natural course of the illnessalone.
We carried out the trial on patients with irritable
bowel syndrome. This is a chronic, functional gastro-
intestinal disorder characterised by recurrent abdom-
inal pain and disturbed bowel function—that is,
diarrhoea, constipation, or alternation between the
two.4 Irritable bowel syndrome is one of the top 10
reasons for seeking primary care and is the reason for
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nearly a third of all consultations with gastro
enterologists,5 with an estimated direct and indirect
cost in the eight major industrial countries of over
$41bn (£20bn, €27bn).6 Irritable bowel syndrome
seemed a suitabledisease to study because previous
randomised controlled trials of treatments have shown
a large positive response (about 40%) in placebo
groups.7 This also suggests that it might be possible to
show a graded response when the three hypothetical
non-specific components of the clinical encounterwere
added individually or in combinations.
METHODS
Study design
We conducted this randomised controlled trial in a
single centre in 262 participants over two study periods
of three weeks (fig 1) For the first three week period,
participants were randomised to one of three groups: a
“waiting list” that controlled for any effects of assess-
ment andobservation (Hawthorneeffects) aswell as the
effects of the natural course of the illnessand regression
to the mean; “limited interaction,” providing placebo
treatment with minimal interaction with the practi-
tioner; or “augmented interaction,” providing placebo
treatment with a defined positive patient-practitioner
relationship.Ourplacebo treatmentwasdeliveredwith
a validated sham acupuncture device. We therefore
assumed that the three study groups represented the
successive addition of the three postulated elements of
the non-specific clinical interactions: group 1 (waiting
list) having only observation alone, group 2 (limited)
adding a dummy treatment, and group 3 (augmented)
adding a warm, empathetic, and confident patient-
practitioner relationship. All participants were evalu-
ated at entry to the trial and after three and six weeks.
At the end of the first three week period, participants
in groups 2 (limited) and 3 (augmented) were, without
their knowledge, randomised a second time in equal
numbers either to continue with sham acupuncture or
to receive genuine acupuncture. Patient-practitioner
relationships for these groups, however, remained the
same. (Results of this nested secondary study, compar-
ing acupuncture and sham acupuncture, in the second
three week period will be reported elsewhere.) Data
from patients in groups 2 and 3 who remained on
placebo for the second period, however, again as
planned prospectively, are included in this report.
Participants ingroup1 (waiting list) remainedon the list
for the second three week period. Results at three
weeks provided data for the primary end point; those
who remained on placebo for the additional three
weeks served to provide observations on non-specific
effects over time.
We randomly assigned participants to the three
study arms using permuted block randomisation with
variable block sizes and assignments provided in
sequentially numbered opaque sealed envelopes. An
administrative assistant, not otherwise involved in the
study, opened the assignment envelopes and recorded
the assignment of each participant in a confidential log.
At three weeks, we used similar methods to randomise
patients in the sham acupuncture groups to continue
shamacupunctureor to switch togenuineacupuncture.
This randomisation was stratified by the level of
abdominal pain at the three week visit (<30 v ≥30 on
a 100 point visual analogue scale).
Recruitment
Participants were recruited from advertisements in the
media, fliers, and referrals from health professionals,
were all at least 18 years old, and met the Rome II
criteria for irritable bowel syndrome8 with a score of
≥150 on the symptom severity scale.9 We excluded
patients if theyhadunexplained findings suchasweight
loss >10% body weight, fever, blood in stools, family
history of colon cancer, or inflammatory bowel
disease; they were also excluded if they had previously
received acupuncture. The diagnosis of irritable bowel
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Fig 1 | Flow of participants through study
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syndrome was based on typical symptoms and
confirmed by a board certified gastroenterologist
experienced in functional bowel disorders (AL) who
also judged the exclusion of patients with alarm
symptoms.10 11 Participants were allowed to continue
medications for irritable bowel syndrome taken before
entering the study (such as fibre, anti-spasmodics, and
loperamide) if this therapeutic regimen had remained
constant for at least the previous 30 days and they
agreed to keep the regimen constant during the trial.
Intervention components
Group 1 (waiting list)
Participants had neither placebo treatment nor inter-
action with a healthcare practitioner but, like other
participants, were assessed at baseline and at three and
six weeks.
Group2 (limited interaction)
Participants received a placebo intervention and
“limited” interaction with a practitioner (see below).
We chose dummy acupuncture for our placebo
because the evidence is that acupuncture has high
placebo effects.12 The validated sham acupuncture is
indistinguishable from acupuncture itself.13 (The shaft
of the shamdevice does not actually pierce the skin but
creates the illusion of doing so because it retracts into a
hollow handle; a small plastic mount and surgical tape
hold the sham needle in place). Placebo treatments
were performed twice aweek, a schedule similar to that
used by many acupuncturists. At each session, six to
eight dummy needles were placed for 20 minutes over
predetermined non-acupuncture points on the arms,
legs, and abdomen; this intervention was the same for
groups 2 (limited) and 3 (augmented).
Thelimited patient-practitioner relationship was
established at the initial visit (duration <5 minutes)
during which practitioners introduced themselves and
stated they had reviewed the patient’s questionnaire
and “knew what to do.” They then explained that this
was “a scientific study” for which they had been
“instructed not to conversewith patients.”Theplacebo
needles were then placed, and the patient left alone in a
quiet room for 20 minutes, a common acupuncture
practice, after which the practitioner returned to
remove the “needles.” Subsequent visits were sched-
uled twice a week for 20 minutes. At week three,
participants completed assessments and those rando-
mised to continue the placebo treatment received an
additional six sham treatments.
Group 3 (augmented interaction)
Participants in group 3 (augmented) also received six
sessions of placebo acupuncture under the same
conditions and in the same room(s) as group 2. Unlike
participants in group 2 (limited), however, they
received an augmented patient-practitioner relation-
ship that began at the initial visit (45minutes’ duration)
and was structured with respect to both content (four
primary discussions) and style (five primary points).
Content included questions concerning symptoms,
how irritable bowel syndrome related to relationships
and lifestyle, possible non-gastrointestinal symptoms,
and how the patient understood the “cause” and
“meaning” of his or her condition. The interviewer
incorporated at least five primary behaviours includ-
ing: a warm, friendly manner; active listening (such as
repeating patient’s words, asking for clarifications);
empathy (such as saying “I can understand how
difficult IBSmustbe foryou”); 20 secondsof thoughtful
silence while feeling the pulse or pondering the
treatment plan; and communication of confidence
and positive expectation (“I have had much positive
experience treating IBS and look forward to demon-
strating that acupuncture is a valuable treatment in this
trial”). We based this intervention model on research
concerning an optimal patient-practit ioner
relationship.14 15 Only after completing this nine item
agendadid the acupuncturist place the placeboneedles
and leave the participant in a quiet room for
20 minutes. On returning, the practitioner “removed”
the placebo needles and exchanged a few words of
encouragement. Specific cognitive and behavioural
interventions that might be beneficial for irritable
bowel syndrome (such as relaxation,16 cognitive
behavioural therapy,17 or education/counselling18)
were not allowed.
Practitioners for group 2 and 3
Thepractitioners in this studyconsistedof four licensed
acupuncturists, all of whom had participated in
previous randomised placebo controlled trials on
acupuncture. The practitioners’ training followed
methods described in earlier studies of structured
patient-physician interactions.19 Practitioners received
20 hours of training to ensure they were able to create
the two different clinical contexts. They were
instructed in advance on the “scripts” for their
Table 1 | Demographics and baseline symptoms in participantswith irritable bowel syndrome.
Figures are number (percentages) unless stated otherwise
Characteristic Waiting list (n=87) Limited (n=88) Augmented (n=87)
Demographics
Mean (SD) age (years) 39 (14) 38 (14) 38 (14)
Women 65 (75) 65 (74) 69 (79)
White 78 (90) 71 (81) 80 (92)
Married/living together 34 (39) 40 (46) 43 (49)
Graduated high school 85 (98) 84 (95) 86 (99)
Employed 71 (82) 63 (72) 74 (85)
Type and duration of irritable bowel syndrome
Constipation 23 (26) 21 (24) 15 (17)
Diarrhoea 22 (25) 18 (21) 29 (33)
Alternating 43 (49) 48 (55) 44 (51)
>1 year 83 (95) 82 (93) 82 (94)
Baseline symptoms
Mean (SD) symptom severity scale 281 (67) 255 (75) 280 (74)
Mean (SD) quality of life 86 (25) 80 (25) 85 (26)
Psychiatric symptoms
Anxiety (SD) 11.6 (9.6) 11.7 (8.8) 13.6 (11.0)
Depression (SD) 3.8 (3.8) 3.2 (3.3) 4.0 (3.9)
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interactions with the two treated groups by means of a
trainingmanual, a video ofmodel sessions, and by role
playing with both simulated and real patients. During
the trial, practitioners also received routine feedback
from the videotaping of all sessions, which was used to
score adherence to protocol (see below). Practitioners
never had contact with participants in group 1 (waiting
list).
Informed consent and blinding
All participants gave written informed consent, but the
consent disclosure omitted certain descriptors of the
trial to protect the study’s scientific validity. Thus,
participants were told that the trial was a placebo
controlled study of acupuncture for irritable bowel
syndrome andwere completely unaware of the study’s
primary aim to examine placebo effects.
Although the trial was prospectively designed to
investigate non-specific effects in irritable bowel syn-
drome, its design included a nested acupuncture
substudy that allowed potential participants in the
“treatment” arms to be told, truthfully, that they had a
50% chance of receiving genuine acupuncture during
the trial. When the study ended, a letter was sent to all
participants explaining the exact purpose of the study
and offering them the opportunity to withdraw their
original consent to use their data. All study personnel,
except the practitioners, were blinded to participant
assignment. Blinded registered nurses who were other-
wise unconnected to the study conducted assessments.
Adherence to treatment
We evaluated the adherence of practitioners to
protocols by videotaping all treatment sessions, of
which 102 (10%of the sample) were randomly selected
for evaluation. We used a well established
procedure.19 20 Two research assistants otherwise
unconnected with the trial separately rated each
session. Reliability between raters was high (κ=0.92),
and 97% of sessions were rated as adherent.
Outcome assessments
Following validatedprocedures in researchon irritable
bowel syndrome, our a priori primary outcome was a
change from baseline at three weeks in the global
improvement scale, which asks participants, “Com-
pared to the way you felt before you entered the study,
have your IBS symptoms over the past 7 days been: (1)
=substantially worse, (2)=moderately worse, (3)
=slightly worse, (4)=no change, (5)=slightly improved,
(6)=moderately improved, or (7)=substantially
improved.”21 22 Our othermain outcomewas adequate
relief,which is a single dichotomous categorisation that
asks participants “Over the past week have you had
adequate relief of your IBS symptoms?”23 24 Neither of
these primary outcomes were measured at baseline.
Our other two outcomes were the symptom severity
scale and thequality of life scale.The symptomseverity
scale is a questionnaire that measures the sum of the
participant’s evaluation on a 100 point scale of each of
five items: severity of abdominal pain, frequency of
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Fig 2 | Outcomes at three week end point
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abdominal pain, severity of abdominal distension,
dissatisfaction with bowel habits, and interferencewith
quality of life.9 All five components contribute equally
to the score, yielding a theoretical range of 0-500, in
which a higher score indicates amore severe condition.
The quality of life scale is a 34 item assessment of the
degree towhich the condition interfereswith apatient’s
quality of life. Each item is rated on a five point Likert
scale and a linear transformation yields a summed
scorewith a theoretical range of 0 to 100, a higher score
indicating better quality of life.25 Side effects were
recorded at each assessment.
Statistical analysis
We estimated a priori that a sample size of 262 would
provide 95% power for finding a significant difference
in scores on the global improvement scale at three
weeks if the augmented, limited, andwaiting list groups
reported improvements of 50%, 40%, and 25%,
respectively. Even if the rates were only 20%, 15%,
and 10%, respectively, however, a sample size of 87 per
group would afford a power of 55%. We replaced
missing data from dropouts using the last observation
carried forward method. We did not, however, carry
forward a baseline observation to week six if a
participant missed assessments at both three and six
weeks.
Theprimary test for eachoutcomemeasurewasa test
of trend examining the ordered alternative hypothesis,
waiting list (group 1)<limited (group 2)<augmented
(group 3). For dichotomous measures, we used
Cochran-Armitage tests. For continuous measures,
we used a Wald test from ordinary least squares
regression models with two independent variables: a
treatment group variable (coded waiting list=1; lim-
ited=2; augmented=3) and the baseline (before treat-
ment) value of the outcome variable. Using a
Bonferroni correction, we considered P<0.0125 (two
sided) to be significant for each test of trend. To better
describe the associationbetweengroupandoutcome, if
the trend test was significant we conducted pairwise
comparisons of the groups—that is, augmented v
limited and limited v waiting list. For the dichotomous
outcomes we used Pearson χ2 tests, and for the
continuous outcomes we used Tukey tests from
analysis of covariance (ANCOVA), again using the
baseline measures of the outcome variables as the
covariate. All analyses were carried out on an intention
to treat basis.
RESULTS
Study population
Between December 2003 and February 2006, we
screened 350 prospective participants of whom 289
wereeligible.Werandomised262people into the three
groups. (Simultaneously, we randomly selected an
additional 27 patients to participate in a parallel
qualitative study of identical assessments and treat-
ments that also included a series of interviews on their
experiences. Prospectively, these participants were
considered a separate study.) At baseline the three
groups were well balanced with regard to demo-
graphics, psychiatric symptoms (as measured by the
Beck anxiety index and the Maier subscale of the
Carroll depression scale), type of irritable bowel
syndrome, and quality of life score (table 1), though
the limited group had lower symptom severity scale
scores. Our data analysis plan included the use of
analysis of covariance for continuousmeasures such as
the symptom severity scale. This adjusts for baseline
differences between individuals and thus provides a
statistical control for group differences when randomi-
sation does not succeed in producing completely
balanced groups on baseline measures.
Outcomes at three weeks
The observed values for all outcome measures were
consistent with our prediction of a progressive
improvement in symptoms among the three groups
such that waiting list was less effective than limited,
which was less effective than augmented. As indicated
in table 2 and figure 2 the test of trend for each of the
outcome measures was significant (P<0.001). For the
global improvement scale and the adequate relief of
symptoms, each of the pairwise comparisons (augmen-
ted v limited and limited v waiting list) was significant
(P<0.001). For the symptom severity score, the
augmented group improved significantly more than
the limitedgroup (P=0.007), but the limitedandwaiting
list groupswere not significantly different (P=0.20).We
observed the same pattern for quality of life (P=0.01
and P=0.58). The proportions of patients reporting
moderate or substantial improvement on the global
improvement scale were 3% (waiting list), 20%
(limited), and 37% (augmented) (P<0.001).
Outcomes at six weeks
For participants in the augmented and limited groups,
the follow-up evaluationwas limited to thosewhowere
randomised to continue placebo treatments. As can be
seen in table 2 and figure 3, each of the tests for trend at
week six was significant. Moreover, except for quality
of life where improvement in thewaiting list groupwas
similar to that in the limited group, the observed values
Table 2 | Outcomemeasuresinparticipantswithirritablebowelsyndromeatthreeandsixweeksas
mean (SD) unless statedotherwise
Outcome measure
Waiting list
(n=87)
Limited
(n=88)
Augmented
(n=87)
P value
for trend
At 3 weeks
Global improvement scale 3.8 (1.0) 4.3 (1.4) 5.0 (1.3) <0.001
% with adequate relief of symptoms 28 44 62 <0.001
Change in symptom severity score 30 (63) 42 (67) 82 (89) <0.001
Change in quality of life 3.6 (8.1) 4.1 (9.4) 9.3 (14.0) 0.001
At 6 weeks
Global improvement scale 3.7 (1.0) 4.6 (1.2) 5.1 (1.5) <0.001
% with adequate relief of symptoms 35 53 61 0.005
Change in symptom severity score 35 (80) 53 (80) 108 (91) <0.001
Change in quality of life 5.5 (10.8) 5.4 (9.9) 12.4 (15.1) 0.002
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for all outcome measures were consistent with our a
priori prediction of order of improvement.
Adverse effects
More than 80%of patients reportedno side effects. The
most common side effects included pain during needle
placement (10%) and redness or swelling (6%) or pain
(5%) after needle removal. At the three week assess-
ment, 2% of patients reported that they considered
increased constipation, increased diarrhoea, and dry
mouth as probably caused by the treatment.Also, up to
1% of patients reported bad dreams, loss of appetite,
sleepiness, fatigue, insomnia, nausea, giddiness, weak-
ness, dizziness, and headache as possibly related to
their treatment.
Blinding
At the three week end point 76% of the limited group
and 84%of the augmented group thought that they had
been treatedwithgenuineacupuncture.This difference
was not significant (P=0.21), suggesting that blinding
was successful. In contrast, at the six week follow-up,
56% of the limited group and 84% of the augmented
group thought that they had been treated with genuine
acupuncture. This difference was significant (P=0.02).
We could not ask any questions about participants’
beliefs about their different group assignment because
they were never told that the study included different
patient-practitioner relationships until the study was
over.
DISCUSSION
In this large prospective study of placebo effects we
found that such effects can be disentangled into three
components that can then be recombined to produce
incremental improvement in symptoms in a manner
resembling a graded dose escalation of component
parts. In the pairwise comparisons, we also found that
an enhanced relationship with a practitioner, together
with the placebo treatment, provides the most robust
effect in terms of the four measures we used. Placebo
treatment with only limited interaction with practi-
tioners was superior to staying on a waiting list with
respect toonly twoof the fourmeasures, suggesting that
the supportive interaction with a practitioner is the
most potent component of non-specific effects.
The magnitude of non-specific effects in the aug-
mented arm is not only statistically significant but also
clearly clinically significant in the management of
irritable bowel syndrome. A decrease in the symptom
severity score of 50 reliably indicates improvement in
symptoms,9 and our study indicates that 61% and 59%
of patients in the augmented arm achieved this level of
improvement at three and six weeks, respectively.
Likewise, the changes we observed in quality of life
indicate at least moderate clinical improvement in
symptoms.25 Finally, the percentage of patients report-
ing adequate relief (62% and 61% at three and six
weeks, respectively) is comparable with the responder
rate in clinical trials of drugs currently used in the
treatment of irritable bowel syndrome.26 27 These
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results indicate that such factors as warmth, empathy,
duration of interaction, and the communication of
positive expectation might indeed significantly affect
clinical outcome. Future investigations will have to
determine the relative importance of each of these
elements of the patient-practitioner relationship.
Limitations
One limitationofour study is thatwecouldnot separate
the effects of observation and assessment (and related
issues like reporting bias). Thus, an additional control
might have been a waiting list group in which
participants were followed without their knowledge.
As setting up such a control group would have been
operationally and ethically difficult to arrange, we
believe that our waiting list group is the only feasible
and best baseline control for estimating the effects of
placebo treatment.
Our outcome measures were subjective rather than
objective. None the less, these measures, including the
global improvement scale and adequate relief of
symptoms are consistent with the recommendations
by the Rome committees for use in trials of irritable
bowel syndrome because no objective measures of
severity are currently available.28 We chose irritable
bowel syndrome for this study because we suspected
that non-specific effects are most likely to be demon-
strable in disorders defined by subjective symptoms
rather than more objective measures of disease.29
Whether our findings apply to other illnesses, includ-
ing those with biochemical or other objective outcome
measures, awaits further study.None the less, our study
has important implications for routine clinical care and
suggests that routine medical care would be less
efficient if patient-practitioner interactions were
reduced. Based on the results of the present study, a
positive patient-practitioner relationship can make a
difference.
Additionally in terms of limitations, it is unclear
whether our placebo outcomes correspond to biologi-
cal changes in irritable bowel syndrome or have any of
the biochemical, neuroendocrine, or neuroanatomical
correlates of placebo response found in recent labora-
tory experiments30 31 or whether our outcomes are
mainly related to shifts in selective attention to diffuse
symptoms.32 In either case, our study represents an
incremental step inplacebo studies and shows that non-
specific effects have a considerable clinical impact.
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